
## CLAIMS

1. A compound of Formula (V-a):




(V-a)

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein:

A is heterocyclyl, or heteroaryl, optionally substituted with one or more $R^1$;

B is heterocyclyl, or heteroaryl, optionally substituted with one or more $R^1$;

wherein each of A and B are not both heterocyclyl or both heteroaryl;

each of $L^1$ and $L^2$ is independently absent, -C(O)-, -N($R^4$)-, -N($R^4$)C(O)-, or -C(O)N($R^4$)-,

Y is N, wherein the dashed lines in the ring comprising Y may be single or double bonds as valency permits;

each $R^1$ is independently hydrogen, $C_1$-$C_6$-alkyl, $C_2$-$C_6$-alkenyl, $C_2$-$C_6$-alkynyl, $C_1$-$C_6$-heteroalkyl, $C_1$-$C_6$-haloalkyl, cycloalkyl, heterocyclyl, aryl, $C_1$-$C_6$ alkylene-aryl, $C_1$-$C_6$ alkenylene-aryl, $C_1$-$C_6$ alkylene-heteroaryl, heteroaryl, halo, cyano, oxo, –$OR^A$, –$NR^BR^C$, –$NR^BC(O)R^D$, –$NO_2$, –$C(O)NR^BR^C$, –$C(O)R^D$, –$C(O)OR^D$, or –$S(O)_xR^D$, wherein each alkyl, alkylene, alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more $R^5$; or

two $R^1$ groups, together with the atoms to which they are attached, form a 3-7-membered cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more $R^5$;

each $R^2$ is independently hydrogen or $C_1$-$C_6$-alkyl;

$R^3$ is $C_1$-$C_6$-alkyl, $C_2$-$C_6$-alkenyl, $C_2$-$C_6$-alkynyl, $C_1$-$C_6$-heteroalkyl, $C_1$-$C_6$-haloalkyl, halo, cyano, –$OR^A$, –$NR^BR^C$, –$C(O)R^D$, or –$C(O)OR^D$;

$R^4$ is hydrogen, $C_1$-$C_6$-alkyl, or $C_1$-$C_6$-haloalkyl;

each $R^5$ is independently $C_1$-$C_6$-alkyl, $C_2$-$C_6$-alkenyl, $C_2$-$C_6$-alkynyl, $C_1$-$C_6$-heteroalkyl, $C_1$-$C_6$-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, oxo, cyano, –$OR^A$, –$NR^BR^C$, –$NR^BC(O)R^D$, –$NO_2$, –$C(O)NR^BR^C$, –$C(O)R^D$, –$C(O)OR^D$, or –$S(O)_xR^D$, wherein each alkyl,

alkenyl, alkynyl, heteroalkyl, haloalkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl is optionally substituted with one or more $R^7$;

$R^{6a}$ and $R^{6b}$ is independently hydrogen, $C_1$-$C_6$-alkyl, $C_1$-$C_6$-heteroalkyl, $C_1$-$C_6$-haloalkyl, or halo;

each $R^7$ is independently $C_1$-$C_6$-alkyl, $C_1$-$C_6$-heteroalkyl, $C_1$-$C_6$-haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, halo, cyano, oxo, or $–OR^A$;

each $R^A$ is independently hydrogen, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ haloalkyl, aryl, heteroaryl, $C_1$-$C_6$ alkylene-aryl, $C_1$-$C_6$ alkylene-heteroaryl, $–C(O)R^D$, or $–S(O)_xR^D$;

each $R^B$ and $R^C$ is independently hydrogen, $C_1$-$C_6$ alkyl, $C_1$-$C_6$ heteroalkyl, cycloalkyl, heterocyclyl, or $–OR^A$; or $R^B$ and $R^C$ together with the atom to which they are attached form a 3-7-membered heterocyclyl ring optionally substituted with one or more $R^9$;

each $R^D$ is independently hydrogen, $C_1$-$C_6$ alkyl, $C_2$-$C_6$ alkenyl, $C_2$-$C_6$ alkynyl, $C_1$-$C_6$ heteroalkyl, $C_1$-$C_6$ haloalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, $C_1$-$C_6$ alkylene-aryl, or $C_1$-$C_6$ alkylene-heteroaryl;

each $R^9$ and $R^{10}$ is independently $C_1$-$C_6$-alkyl or halo;


n is 0, 1, or 2;


m is 0, 1, 2, or 3; and

x is 0, 1, or 2.


2. The compound of claim 1, wherein A is heteroaryl.

3. The compound of claim 1, wherein A is selected from















, and













, wherein $R^1$ is as described in claim 1.





4. The compound of any one of claims 1-2, wherein A selected from






 ,  ,  ,  ,


 ,  ,  ,  ,

 ,  ,  ,  ,  ,

 ,  ,  ,  ,





 ,  ,  ,  ,





 ,  ,  ,  ,  ,






and  , wherein $R^1$ is as described in claim 1.





5. The compound of any one of claims 1-4, wherein B is heterocyclyl.




6. The compound of any one of claims 1-4, wherein B is selected from



 ,  ,  ,  ,




 ,  ,  ,  ,


 ,  ,  ,  ,  ,


 ,  ,  ,  ,







 ,  ,  ,


 ,  , , ,

 , ,  ,  ,  ,

and  , wherein $R^1$ is as described in claim 1.


7. The compound of any one of claims 1-5, wherein B is selected from  ,

 ,  ,  ,  ,  ,  , and

 , wherein $R^1$ is as described in claim 1.

8. The compound of any one of claims 1-7, wherein each of $L^1$ and $L^2$ is independently absent.





9. The compound of any one of claims 1-8, wherein the compound of Formula (V-a) is a compound of Formula (V-c):
















(V-c)







or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof, wherein: m is 0, 1 or 2; and where A, B, $L^1$, $R^2$, $R^3$, and subvariables thereof are as defined in claim 1.







10. The compound of any one of claims 1-9, wherein the compound of Formula (V-a) is a compound selected from one of the following compounds:







| **Compound No.** | **Structure** |
|---|---|
| **186** |  |
| **248** |  |
| **249** |  |
| **250** |  |







| | |
|---|---|
| **251** |  |
| **253** |  |
| **254** |  |
| **255** |  |
| **256** |  |
| **257** |  |


| | |
|---|---|
| **258** |  |
| **259** |  |
| **260** |  |
| **261** |  |
| **262** |  |
| **263** |  |

| | |
|---|---|
| **264** |  |
| **265** |  |
| **266** |  |
| **271** |  |
| **272** |  |
| **273** |  |

| | |
|---|---|
| **274** |  |
| **275** |  |
| **277** |  |
| **278** |  |
| **279** |  |
| **280** |  |

| | |
|---|---|
| **283** |  |
| **304** |  |
| **305** |  |
| **312** |  |
| **324** |  |
| **325** |  |

| | |
|---|---|
| **326** |  |
| **328** |  |
| **329** |  |
| **330** |  |
| **331** |  |
| **335** |  |

| | |
|---|---|
| **336** |  |

or a pharmaceutically acceptable salt, solvate, hydrate, tautomer, or stereoisomer thereof.

11. A pharmaceutical composition comprising a compound of any one of claims 1-10 and a pharmaceutically acceptable excipient.

12. The compound of any one of claims 1-10 or the pharmaceutical composition of claim 11, wherein the compound alters, binds to, or stabilizes a target nucleic acid.

13. The compound of any one of claims 1-10 or the pharmaceutical composition of claim 11, wherein the compound increases or decreases splicing at splice site on a target nucleic acid, by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more.

14. A method of modulating splicing of a nucleic acid comprising contacting the nucleic acid with a compound of Formula (V-a), according to any one of claims 1-10 or the pharmaceutical composition of claim 11.

15. The method of claim 14, wherein the compound increases or decreases splicing at splice site on a target nucleic acid, by about 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or more.

16. A method of forming a complex comprising a component of a spliceosome, a nucleic acid, and a compound of Formula (V-a):

comprising contacting the nucleic acid with a compound of Formula (V-a), according to any one of claims 1-10 or the pharmaceutical composition of claim 11.

17. The method of claim 16, wherein the component of a spliceosome is recruited to the nucleic acid in the presence of the compound of Formula (V-a).

18. A method of altering the conformation of a nucleic acid comprising contacting the nucleic acid with a compound of Formula (V-a), according to any one of claims 1-10 or the pharmaceutical composition of claim 11.

19. The method of claim 18, wherein the altering comprises forming, stabilizing, or reducing a bulge in the nucleic acid.

20. The method of any one of claims 18-19, wherein the nucleic acid comprises a splice site.

21. A use of a compound of Formula (V-a) according to any one of claims 1-10 or the pharmaceutical composition of claim 11 in the manufacture of a medicament for treating a disease or disorder, wherein the disease or disorder comprises a proliferative disease, a neurological disease, autoimmune disorder, immunodeficiency disorder, lysosomal storage disease, cardiovascular condition, metabolic disorder, respiratory condition, renal disease, or infectious disease.

22. The use of claim 21, wherein the disease or disorder comprises a proliferative disease (e.g., cancer, a benign neoplasm, or angiogenesis).

23. The use of claims 21, wherein the disease or disorder comprises a neurological disease, autoimmune disorder, immunodeficiency disorder, lysosomal storage disease, cardiovascular condition, metabolic disorder, respiratory condition, renal disease, or infectious disease.